Compare UCTT & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | PGEN |
|---|---|---|
| Founded | 1991 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2004 | 2013 |
| Metric | UCTT | PGEN |
|---|---|---|
| Price | $78.76 | $8.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $137.00 | $13.65 |
| AVG Volume (30 Days) | 667.6K | ★ 3.6M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $1,734,500,000.00 | $230,981,000.00 |
| Revenue This Year | $32.58 | $2,365.68 |
| Revenue Next Year | $42.02 | $85.75 |
| P/E Ratio | ★ N/A | $271.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.49 | $2.99 |
| 52 Week High | $144.22 | $8.27 |
| Indicator | UCTT | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.06 | 72.48 |
| Support Level | $70.18 | $6.41 |
| Resistance Level | $84.43 | N/A |
| Average True Range (ATR) | 3.11 | 0.45 |
| MACD | 1.65 | 0.09 |
| Stochastic Oscillator | 86.74 | 84.01 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.